Clik here to view.
日本自動車研究所の小野古志郎博士が自動車医学振興協会から功労賞を受賞
シカゴ （ビジネスワイヤ）– 交通事故関連の救命と傷害撲滅に注力する世界的で学際的な専門家組織の自動車医学振興協会（AAAM）は本日、日本自動車研究所（JARI）の研究顧問兼所長補佐の小野古志郎博士が2016年の功労賞の受賞者に選ばれたと発表しました。この功労賞はAAAMの最高賞であり、自動車医学の側面に長年にわたり大きな科学的貢献をされたか、一つの卓越した貢献をされた優れた個人に贈られます。...
View ArticleClik here to view.
ASLAN Pharmaceuticals Enters Service Agreement with Selexis SA for...
GENEVA & SINGAPORE Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, and ASLAN Pharmaceuticals, a biotech company...
View ArticleClik here to view.
Orthofix Announces Japanese Approval and Market Launch of PHOENIX Minimally...
LEWISVILLE, Texas Orthofix International N.V. (NASDAQ:OFIX), a diversified, global medical device company, today announced regulatory approval from the Japanese Ministry of Health, Labor and Welfare...
View ArticleClik here to view.
Acelity to Offer New Gelling Fiber Advanced Wound Dressing
SAN ANTONIO Acelity, a global advanced wound care and regenerative medicine company, announced today that BIOSORB™ Gelling Fiber Dressing is now available in the United States and has Conformité...
View ArticleClik here to view.
Second Sight Announces Two Exclusive Distribution Agreements to Bring the...
SYLMAR, Calif. Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to restore some useful...
View ArticleClik here to view.
Astellas Launches DigiTx Partners, a Digital Health Investment Company in...
TOKYO & SAN FRANCISCO Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) and DigiTx Partners LLC (CEO: David Kim, “DigiTx Partners”) announce that Astellas has launched...
View ArticleClik here to view.
Astellas Reports First Quarter Financial Results of FY2016
TOKYO Astellas Pharma Inc. (TOKYO:4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced financial results for the first quarter of fiscal year 2016 ending March 31, 2017...
View ArticleClik here to view.
Takeda Reports 1st Quarter 2016 Results with a Strong Start to the Year and...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502): Strong first quarter results and confidence in Management Guidance • Underlying revenue grew +9.1%, driven by a +15.3% increase...
View ArticleClik here to view.
武田薬品：2016年度第1四半期の連結業績について力強いスタートで年間マネジメントガイダンスを堅持
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社 （東証：4502）： 2016年度第1四半期（4-6月期）の力強い業績により、年間マネジメントガイダンスを堅持...
View ArticleClik here to view.
Hoya Reports First Quarter Financial Results
TOKYO HOYA Corporation (TOKYO: 7741) today announced financial results for the first quarter ended June 30, 2016. During the quarter, revenues totaled 115,165 million yen, representing a decline of...
View ArticleClik here to view.
武田公布2016财年第一季度业绩，财年开局喜人，有信心实现管理层指引
日本大阪 (美国商业资讯)–武田药品工业株式会社(TOKYO:4502)： 强劲的第一季度业绩，有信心实现管理层指引 • 基础营收增长+9.1%，得益于武田增长引擎（胃肠药、肿瘤药、CNS和新兴市场）+15.3%的增长。（根据报告的营收下降-2.8%，至4,340亿日元，归咎于撤资和货币影响） •...
View ArticleClik here to view.
Chi-Med and AstraZeneca Amend Co-development Agreement to Accelerate...
LONDON Chi-Med and AstraZeneca today announced an amendment (the “Amendment”) to the 2011 global licensing, co-development, and commercialisation agreement (the “2011 Agreement”) regarding...
View ArticleClik here to view.
Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA...
BOTHELL, Wash. & CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that the Phase 3 ALCANZA clinical...
View ArticleClik here to view.
Central Orthodontic Clinic: Revolution in Orthodontics Accomplished with KILBON
SEOUL, South Korea KILBON, so-called next-generation orthodontics has recently become the hottest issue as it is very innovative to correct severe dentoalveolar protrusion and hyperdivergent face at...
View ArticleClik here to view.
Hutchison China MediTech Limited (“Chi-Med”) Reports Interim Results for the...
LONDON Chi-Med (AIM/NASDAQ: HCM), the China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the global market,...
View ArticleClik here to view.
Hutchison China MediTech Limited (“Chi-Med”): Change of Non-executive Directors
LONDON Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from August 1, 2016, Dr Dan Eldar has been appointed as a Non-Executive Director of Chi-Med in place...
View ArticleClik here to view.
武田与Seattle Genetics发布ADCETRIS® (Brentuximab...
华盛顿州博瑟尔、马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(TSE:4502)与Seattle Genetics, Inc. (NASDAQ:SGEN)今天宣布，评估ADCETRIS (brentuximab...
View ArticleClik here to view.
武田薬品とシアトル・ジェネティクスがCD30発現皮膚T細胞リンパ腫でアドセトリス（ブレンツキシマブ・ベドチン）を検討する第3相ALCANZA臨床試験の良好...
米ワシントン州ボセル & マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
Nativis, Inc. Enters into Evaluation Agreement with Major Japan-Based...
SEATTLE Nativis, Inc., a clinical stage life sciences company developing non-invasive, medical device therapies for cancers and other serious diseases, today announced that it has entered into an...
View ArticleClik here to view.
Osprey Medical Announces Oversubscribed A$28 Million Private Placement
MINNEAPOLIS & MELBOURNE, Australia Osprey Medical, Inc. (ASX:OSP) (Osprey or Company) today announces that it has received commitments from sophisticated and institutional investors to subscribe...
View Article